title: In vitro activity of JPC 2067 alone and in combination with sulfamethoxazole against nocardia species.
abstract: JPC 2067 is a novel dihydrotriazine dihydrofolate reductase inhibitor that is being developed as an antimalarial therapeutic. We evaluated the in vitro activity of JPC 2067 alone and in combination with sulfamethoxazole (SMX) against a panel of nocardia isolates. The MIC(50)s and MIC(90)s for JPC 2067, SMX, and the combination were 0.125 μg/ml and 4 μg/ml, 16 μg/ml and 32 μg/ml, and 0.03 μg/ml and 2 μg/ml, respectively. JPC 2067 alone and in combination with SMX should be evaluated further to understand its clinical potential.
authors: Department of Medicine, VAMC, Syracuse, New York, USA.
authors: Swagatam
authors: S
authors: Mookherjee
authors: Carolyn
authors: C
authors: Shoen
authors: Michael
authors: M
authors: Cynamon
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards; D009615:Nocardia / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D009617:Nocardia Infections / Q000382:microbiology*; D013420:Sulfamethoxazole / Q000494:pharmacology*; D013762:Tetrahydrofolate Dehydrogenase / Q000187:drug effects; D014227:Triazines / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D014227:Triazines; D013762:Tetrahydrofolate Dehydrogenase; D013420:Sulfamethoxazole